Researchers at The Second Qilu Hospital of Shandong University reported a microfluidic approach that improves CAR-T cell transduction efficiency under low viral-dose conditions. The work targets a core manufacturing bottleneck for CAR-T production: cost, time, and scalability of the genetic delivery step. By reducing the reliance on higher viral doses while maintaining effective gene transfer, the method aims to compress manufacturing constraints that have limited broader access. The study’s emphasis on microfluidic process control also signals a broader push to engineer the manufacturing unit operations rather than rely solely on new vectors or cell inputs. If translated, the platform could support more consistent production batches and potentially lower per-patient manufacturing burden for CD19-targeting CAR-T programs.